184 related articles for article (PubMed ID: 35877722)
21. Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Li P; Basnet SK; Kumarasiri M; Diab S; Teo T; Albrecht H; Wang S
Eur J Med Chem; 2015 May; 95():116-26. PubMed ID: 25800647
[TBL] [Abstract][Full Text] [Related]
22. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2.
Knauf U; Tschopp C; Gram H
Mol Cell Biol; 2001 Aug; 21(16):5500-11. PubMed ID: 11463832
[TBL] [Abstract][Full Text] [Related]
23. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
[TBL] [Abstract][Full Text] [Related]
24. Biological Evaluation of Selected Flavonoids as Inhibitors of MNKs Targeting Acute Myeloid Leukemia.
Chen LC; Huang HL; HuangFu WC; Yen SC; Ngo ST; Wu YW; Lin TE; Sung TY; Lien ST; Tseng HJ; Pan SL; Huang WJ; Hsu KC
J Nat Prod; 2020 Oct; 83(10):2967-2975. PubMed ID: 33026809
[TBL] [Abstract][Full Text] [Related]
25. MNK1 and MNK2 Expression in the Human Dorsal Root and Trigeminal Ganglion.
Shiers S; Sahn JJ; Price TJ
Neuroscience; 2023 Apr; 515():96-107. PubMed ID: 36764601
[TBL] [Abstract][Full Text] [Related]
26. Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a).
Stead RL; Proud CG
FEBS Lett; 2013 Aug; 587(16):2623-8. PubMed ID: 23831578
[TBL] [Abstract][Full Text] [Related]
27. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Grzmil M; Seebacher J; Hess D; Behe M; Schibli R; Moncayo G; Frank S; Hemmings BA
Cell Signal; 2016 Sep; 28(9):1412-1421. PubMed ID: 27289018
[TBL] [Abstract][Full Text] [Related]
29. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503
[TBL] [Abstract][Full Text] [Related]
30. Update on the Development of MNK Inhibitors as Therapeutic Agents.
Xu W; Kannan S; Verma CS; Nacro K
J Med Chem; 2022 Jan; 65(2):983-1007. PubMed ID: 34533957
[TBL] [Abstract][Full Text] [Related]
31. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
33. Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway.
Chen C; Cheng CD; Wu H; Wang ZW; Wang L; Jiang ZR; Wang AL; Hu C; Dong YF; Niu WX; Qi S; Qi ZP; Liu J; Wang WC; Niu CS; Liu QS
Acta Pharmacol Sin; 2021 Jan; 42(1):108-114. PubMed ID: 32398685
[TBL] [Abstract][Full Text] [Related]
34. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.
Li Y; Yue P; Deng X; Ueda T; Fukunaga R; Khuri FR; Sun SY
Neoplasia; 2010 Oct; 12(10):848-55. PubMed ID: 20927323
[TBL] [Abstract][Full Text] [Related]
35. Development of an Imidazopyridazine-Based MNK1/2 Inhibitor for the Treatment of Lymphoma.
Yuan X; Guan D; Chen C; Guo S; Wu H; Bu H; Yang CY; Wang M; Zhou J; Zhang H
J Med Chem; 2024 Apr; 67(7):5437-5457. PubMed ID: 38564512
[TBL] [Abstract][Full Text] [Related]
36. Roles of mitogen-activated protein kinase signal-integrating kinases 1 and 2 in oxidant-mediated eIF4E phosphorylation.
Shenberger JS; Zhang L; Hughlock MK; Ueda T; Watanabe-Fukunaga R; Fukunaga R
Int J Biochem Cell Biol; 2007; 39(10):1828-42. PubMed ID: 17689282
[TBL] [Abstract][Full Text] [Related]
37. A novel inhibitor stabilizes the inactive conformation of MAPK-interacting kinase 1.
Matsui Y; Yasumatsu I; Yoshida KI; Iimura S; Ikeno Y; Nawano T; Fukano H; Ubukata O; Hanzawa H; Tanzawa F; Isoyama T
Acta Crystallogr F Struct Biol Commun; 2018 Mar; 74(Pt 3):156-160. PubMed ID: 29497019
[TBL] [Abstract][Full Text] [Related]
38. Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.
Dolniak B; Katsoulidis E; Carayol N; Altman JK; Redig AJ; Tallman MS; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Platanias LC
J Biol Chem; 2008 May; 283(18):12034-42. PubMed ID: 18299328
[TBL] [Abstract][Full Text] [Related]
39. Mnk inhibitors: a patent review.
Abdelaziz AM; Yu M; Wang S
Pharm Pat Anal; 2021 Jan; 10(1):25-35. PubMed ID: 33441033
[TBL] [Abstract][Full Text] [Related]
40. MAP kinase-interacting kinases--emerging targets against cancer.
Diab S; Kumarasiri M; Yu M; Teo T; Proud C; Milne R; Wang S
Chem Biol; 2014 Apr; 21(4):441-452. PubMed ID: 24613018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
